Format

Send to

Choose Destination
BMC Cancer. 2019 May 2;19(1):413. doi: 10.1186/s12885-019-5624-2.

Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.

Author information

1
Department of Thoracic Surgery, Thoraxklinik, Heidelberg University, Roentgenstraße 1, 69126, Heidelberg, Germany.
2
Translational Lung Research Center (TLRC), Member of German Center for Lung Research (DZL), Heidelberg, Germany.
3
Department of Thoracic Oncology, Thoraxklinik, Heidelberg University, Heidelberg, Germany.
4
Institute of Pathology, Heidelberg University, Heidelberg, Germany.
5
Divison of Thoracic Surgery, Technical University of Munich, Munich, Germany.
6
Department of Thoracic Surgery, Thoraxklinik, Heidelberg University, Roentgenstraße 1, 69126, Heidelberg, Germany. martin.eichhorn@med.uni-heidelberg.de.
7
Translational Lung Research Center (TLRC), Member of German Center for Lung Research (DZL), Heidelberg, Germany. martin.eichhorn@med.uni-heidelberg.de.

Abstract

BACKGROUND:

Immunotherapies targeting the PD1/PD-L1 pathway have had a large impact on the treatment of advanced NSCLC. Concerning multimodality tumor therapy, only few trials until today have been performed investigating neoadjuvant treatment with anti PD-1 immunotherapy prior to curative intent surgery. Aim of the NEOMUN investigator initiated trial (EudraCT-Number: 2017-000105-20; ClinicalTrials.gov Identifier: NCT03197467) is to assess feasibility and safety of pre-surgical anti PD-1 treatment in order to improve long term survival.

METHODS:

The study is designed as an open-label, single arm, prospective, monocenter, phase II study including 30 patients with NSCLC stage II/IIIA suitable for curative intent surgery. Investigational drug is Pembrolizumab. After 2 cycles of immunotherapy (à 200 mg q3w i.v.), tumor resection with lobectomy or bilobectomy will be performed. Primary objectives are to assess the feasibility and safety of a neoadjuvant immunotherapy and to assess antitumor activity of Pembrolizumab with regard to clinical and pathological tumor response. Secondary objective is disease free and overall survival. Exploratory objective is to analyze potential predictive biomarkers and to evaluate the therapeutic efficacy of Pembrolizumab by extended immune cell and cytokine analysis of tumor tissue. The study protocol was approved by the local ethics committee and the federal authority. Start of patient enrollment is scheduled for June 2018.

DISCUSSION:

The NEOMUN trial will be one of the first clinical trials investigating a multimodal treatment strategy including neoadjuvant immunotherapy using Pembrolizumab as an investigational drug. Assessing the safety and therapeutic potential of neoadjuvant immunotherapy in connection with lung surgery will be of great interest for thoracic surgeons.

TRIAL REGISTRATION:

Prospectively, the NEOMUN study has been registered on www.clinicaltrials.gov ; NCT03197467 (first post: June 23rd, 2017).

KEYWORDS:

Checkpoint inhibitor; NSCLC; Neoadjuvant immunotherapy; Pembrolizumab; Thoracic surgery

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center